Overview

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

Status:
Terminated

Trial end date:
2017-09-05

Target enrollment:

Participant gender:

Summary

This clinical research study is being carried out in two parts, Phase 1 and Phase 2. The primary purpose of the Phase 1 portion of the study is to observe the safety of the combination of rociletinib and MPDL3280A in EGFR-mutant NSCLC patients. The primary purpose of the Phase 2 portion of the study is to evaluate the safety and anti-tumor effects of the combination of rociletinib and MPDL3280A, at the best doses for the combination determined in Phase 1, in patients with EGFR-mutant NSCLC.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Clovis Oncology, Inc.

Collaborator:

Genentech, Inc.

Treatments:

Antibodies, Monoclonal
Atezolizumab